Bax channel blockers are primarily used in research and therapeutic contexts to study and modulate apoptosis, the process of programmed cell death. By inhibiting the activity of Bax proteins, these blockers can prevent the release of cytochrome c from mitochondria, a key step in the apoptotic pathway. This makes them valuable tools in understanding cellular mechanisms and developing treatments for diseases characterized by excessive cell death, such as neurodegenerative disorders like Alzheimer's and Parkinson's. Additionally, they are explored in cancer research to protect healthy cells from apoptosis induced by chemotherapy, potentially reducing side effects. Their application also extends to ischemia-reperfusion injury, where they may help minimize tissue damage by preventing apoptosis in affected cells.